4th Jun 2015 07:12
LONDON (Alliance News) - Vectura Group PLC said Thursday that patient enrolment has begun for its phase I study of VR942-1-001 for the treatment of asthma.
The trial is part of an agreement between Vectura and Belgium's UCB SA signed in September 2013 to develop VR942 towards a phase II clinical proof-of-concept.
Financial terms of the collaboration have not been disclosed.
"The start of clinical evaluation of this innovative and differentiated candidate is a very positive step and we look forward to further progress in the future. This achievement is underpinned by an excellent collaborative relationship, combining the development strengths of Vectura and UCB," said Chief Executive Chris Blackwell in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L